Product logins

Find logins to all Clarivate products below.


Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson Innovative Medicine’s Tremfya, AbbVie’s Skyrizi) are fiercely competing with the established agents Humira and Stelara, effectively earning a strong position in a crowded market due to their greater efficacy, more-convenient dosing, and faster onset of action. The availability of BMS’s oral TYK2 inhibitor Sotyktu and UCB’s IL-17 A/F dual inhibitor Bimzelx has expanded dermatologists’ treatment armamentarium and increased competition among targeted therapies. Moreover, several oral—and thus more-convenient—agents for psoriasis, including piclidenoson, which has a novel mechanism of action, are expected to launch, further fueling competition in this space. Nevertheless, substantial unmet need in the treatment of psoriasis remains (e.g., agents that induce long-term remission for patients with severe disease, more-affordable therapies for patients with mild disease).

QUESTIONS ANSWERED

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq / Lumicef, Bimzelx) and the IL-23 inhibitors (Tremfya, Ilumya, Skyrizi), and where are / will these agents be positioned in the psoriasis treatment algorithm?
  • How is the oral TYK2 inhibitor Sotyktu affecting apremilast’s (Amgen’s Otezla) patient share, and how do the two agents compare on efficacy and safety attributes?
  • How does the availability of adalimumab biosimilars in the United States impact the psoriasis market?
  • What unmet needs remain in the treatment of psoriasis? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…